Featured News
LuGENE® Lupus Test Launches to Predict Flares & Drug Targets
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
Virginia Workforce Award to AMPEL BioSolutions
AMPEL on Bloomberg Markets
Lupus, coronary artery disease share genetic risk factors; data may lead to early testing
Innovator-of-Year to AMPEL
RNA-Based Precision Health: AMPEL’s Blood & Biopsy Tests
AMPEL BioSolutions’ Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer.
AMPEL BioSolutions’ Machine Learning Breakthrough Predicts Chronic Disease Flares from a Blood Sample
AMPEL’s Genomic Platform: A Physician’s POV
Cville Company Uses Genetics and Big Data to Find Better Medical Treatments
Getting approval for new drugs takes years and costs companies millions of dollars. What’s more, clinical trials sometimes fail, leaving firms with nothing to show. Now, however, a Virginia company is taking a different approach – looking at drugs that already have FDA approval to see what other conditions they might treat.
AMPEL BioSolutions Latest Innovation in Precision Medicine Predicts Drug Options Using RNA Analytics and Machine Learning
A breakthrough in precision and customized medicine, announced by AMPEL BioSolutions, may update how physicians treat patients with various illnesses, including cancer, infectious disorders, and autoimmune.
Bloomberg’s “The Tape” Personalized Precision Medicine (Audio)
Dr. Amrie Grammer, co-founder of AMPEL BioSolutions, joins the show to discuss biotech and her company Hosted by Paul Sweeney and Matt Miller.
Health + Tech – Future of Precision Medicine With Dr. Amrie Grammer
CLICK FOR ORIGINAL ARTICLE >
Dr. Amrie Grammer, co-founder, president and chief scientific officer of AMPEL BioSolutions, joins hosts Holly Buckley and Kristen McDermott Woodrum on this episode of Health+Tech.
AMPEL BioSolutions Announces Gene-Based Lupus Diagnostic At Biotech Showcase In San Francisco
AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.
MI/AL for Diagnosis & Prognosis
Presentation by Amrie Grammer, Ph.D, COO/CSO, AMPEL BioSolutions at the Precision Medicine World Conference on June 28, 2022
AMPEL BioSolutions focused on developing clinical blood test predicts the correct drug for a patient
AMPEL BioSolutions’ Co-Founder and COO/CSO Dr. Amrie Grammer today at the Biotech Showcase at JP Morgan Healthcare announces the kickoff of a Series A $12.5M raise to commercialize LuGENETM, a gene-based diagnostic.